miRNA expression and clinicopathological parameters.

This table demonstrates that although miR-29a, miR-181a and miR-652 are under-expressed in women with Luminal A-like breast tumors, there is no significant difference in miRNA expression levels in the blood of women with breast cancer, regardless of stage of disease (1 to 5), grade of disease (1 to 3) or nodal status (positive or negative). This is an important biomarker trait, as it reflects miRNA expression alteration in early, as well as late stage disease.
*p-value determined by one-way ANOVA.